LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Dr. Falk Pharma GmbH
Headquarters:
Freiburg, Germany
Website:
https://drfalkpharma.com/en/...
Year Founded:
1960
Status:
Private
BioCentury
|
Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
Read More
BioCentury
|
Aug 1, 2023
Deals
Pharma deals seek novelty with heavy focus on first in class
An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
Read More
BioCentury
|
Oct 21, 2022
Politics, Policy & Law
Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool
Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
Read More
BioCentury
|
Feb 27, 2019
Finance
Calypso finds its rhythm
How rising interest in IL-15 helped six-year-old Calypso close its series A
Read More
BioCentury
|
Jun 16, 2017
Company News
GeneriCo wins IPR for Apriso
Read More
BioCentury
|
Jul 11, 2016
Clinical News
Rifamycin SV MMX: Phase III data
Read More
BioCentury
|
Oct 12, 2015
Company News
Lipid Therapeutics, Nestle deal
Read More
BioCentury
|
Aug 17, 2015
Finance
Medigene remade
How Medigene found new investors by focusing exclusively on immunotherapy
Read More
BioCentury
|
May 25, 2015
Clinical News
Trichuris suis ova: Development discontinued
Read More
BioCentury
|
Nov 17, 2014
Clinical News
LT-02: Phase III started
Read More
Items per page:
10
1 - 10 of 71